

New HCV/HBV prevalence (*and incidence*) data from Latvia



Anda Kivite, PHD, MPH

National DRID expert, Reitox focal point, Centre for Disease prevention and Control of Latvia
Assistant Professor, Department of Public Health and Epidemiology, Riga Stradins University



RĪGAS STRADIŅA
UNIVERSITĀTE

VITA BREVIS ARS LONGA

HCV/HBV elimination “barometer”


CONTEXTS AND NEEDS

Indicators:

- prevalence of HCV/HBV among PWID,
- size of the PWID population,
- pattern of drug use:
 - main substances injected,
 - sharing of syringes / paraphernalia within last 4 weeks

Data sources:

- surveys,
- routine diagnostic testing



HCV/HBV elimination “barometer”


IMPACT

Indicators:

- incidence of HCV/HBV among PWID,
- prevalence of chronic HCV/HBV among young and/or recent PWID (proxy for incidence)

Data sources:

- cohort studies,
- surveys or routine diagnostic testing



Data sources


■ Riga Drug User's Cohort Study (RDUCS):

- Launched in 2006, in 2018 - the 11th wave of the study (latest data available – 2017)
- HCV, HBV (HBsAg) rapid testing – in 2014, 2016, 2017
- People with positive tests – not tested repeatedly during the next waves
- Sample size: ~550 (~350 tested)

■ Diagnostic testing – 12 NEP/LTCs:


- Reporting data via electronical system
- ~750 PWID tested for HCV and ~950 for HBV (HBsAg rapid tests)

Sites




CONTEXTS AND NEEDS

Prevalence of HCV – cohort study vs diagnostic testing



CONTEXTS AND NEEDS


Prevalence of HBV – cohort study vs diagnostic testing



CONTEXTS AND NEEDS


Size of the PWID population

- Treatment multiplier method (data – from the cohort study)




CONTEXTS AND NEEDS

Main substances injected (*amphetamines within last 30 days*)




CONTEXTS AND NEEDS

Sharing of syringes / paraphernalia within last 4 weeks – cohort only



IMPACT

Incidence (% per year) of HCV among PWID




HBV – n = too small

1	2	3	4	5	6	7	8	9	10
Riga	Riga	Riga	Bauska	Riga	Riga	Riga	Riga	Riga	Riga
male	female	male	male	female	male	male	female	male	male
49	38	46	26	27	24	28	26	24	48
years	years	years	years	years	years	years	years	years	years
heroin	amph	amph	heroin	amph	amph	amph	amph	amph	heroin
30	22	26	4	6	4	6	5	4	30
years	years	years	years	years	years	years	years	years	years
inj.	inj.	inj.	inj.	inj.	inj.	inj.	inj.	inj.	inj.


IMPACT

Prevalence of chronic HCV among young (<25 years) PWID (proxy for incidence)



IMPACT

Prevalence of chronic HCV among recent (<2 years) PWID (proxy for incidence) – DT only



Problems

- Rapid testing \neq confirmed diagnosis
- DT clients \neq participants of cohort study
- DT data \neq prevalence data
- Cohort \neq prevalence data
- Estimated number of PWID – biased if based on data from the cohort study
- How to choose between cohort and repeated RDS?
- **Conclusion – the truth is still out there**





Latvija

100



Paldies par uzmanību! Thank you!